A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT02911948

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02911948
Other papers using this trial's data
  • Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial Diabetes, obesity & metabolism, 2019-12 DOI, PubMed 31423685, PMC6900157 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02911948. Randomized; double masking; primary purpose treatment. Start 2016-09-21 (actual); primary completion 2017-11-17 (actual). Results posted on 2019-03-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Acronym
DUAL™ II Japan
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin degludec/liraglutide
Intervention (Drug)
Insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02911948
Content hash
52c55629be99b832e36c43f06af7a6e03f7b653890c3cad62cf40adec2c3a933